Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Citius Oncology, Inc. Common Stock

CTOR

Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.54 – $0.61
Volume 120,538
Market cap $57M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$57.11M
Price / earnings
—
Price / book
1.41×
Price / sales
8.04×
EV / sales
6.61×
EV / EBITDA
-0.99×

Profitability

Earnings per share
-$0.44
Return on assets
-41.09%
Return on equity
-114.06%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.16×
Current ratio
0.73×
Quick ratio
0.34×
Cash ratio
0.28×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.39M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CTOR, quarterly periods
Line itemQ3 FY2026 Jun 30, 2026Q2 FY2026 Mar 31, 2026Q1 FY2026 Dec 31, 2025Q4 FY2025 Sep 30, 2025Q3 FY2025 Jun 30, 2025Q2 FY2025 Mar 31, 2025Q1 FY2025 Dec 31, 2024Q4 FY2024 Sep 30, 2024
Revenue$1.49M$1.67M$3.94M$0$0$0$0$0
Cost of revenue$491.84K$328.88K$789.21K$0$0$0$0$0
Gross profit$1M$1.34M$3.15M$0$0$0$0$0
Selling, general and administrative$7.78M$23.63M$6.82M$3.64M$4.01M$2.24M$5.13M$5.37M
Research and development$218.5K$1.08M$1.02M$1.08M$938.28K$3.14M$1.26M$1.3M
Total operating expenses$9.72M$29.95M$8.41M$4.71M$4.94M$7.47M$6.39M$6.67M
Operating income-$8.72M-$28.61M-$5.25M-$4.71M-$4.94M-$7.47M-$6.39M-$6.67M
Interest expense-$231.73K-$33.03K-$45.84K-$57.28K-$160.76K$0$0$0
Income before taxes-$9.03M-$26.84M-$5.27M-$4.73M-$5.11M-$7.47M-$6.39M-$6.67M
Income taxes-$107.35K-$231.21K$264.24K$264.24K$264.24K$264.24K$264.24K$144K
Net income-$8.92M-$26.61M-$5.53M-$5M-$5.37M-$7.74M-$6.66M-$6.81M
Net income attributable to common shareholders-$8.92M-$26.61M-$5.53M-$5M-$5.37M-$7.74M-$6.66M-$6.81M
EBITDA-$8.72M-$29.19M-$4.68M-$4.71M-$4.94M-$7.47M-$6.39M-$6.67M
Basic earnings per share-$0.08-$0.27-$0.06-$0.06-$0.08-$0.11-$0.09-$0.10
Diluted earnings per share-$0.08-$0.27-$0.06-$0.06-$0.08-$0.11-$0.09-$0.10

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Citius Pharmaceuticals reported its first revenue of $3.9 million in Q1 2026 following the December 2025 launch of LYMPHIR by its majority-owned subsidiary Citius Oncology. The drug, approved for treating relapsed or refractory cutaneous T-cell lymphoma, has begun initial sales through a nationwide distributor network. The company raised $20.9 million in equity financing and is advancing late-stage pipeline candidates Mino-Lok and Halo-Lido while exploring international expansion and combination therapy opportunities.

Benzinga

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Citius Oncology reported its first revenue of $3.9 million following the successful December 2025 U.S. commercial launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma. The company established nationwide distribution infrastructure and deployed an AI-enabled commercial platform. Despite positive commercial progress, the company reported a net loss of $5.5 million for Q1 2026 and held $7.3 million in cash as of December 31, 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.